1. As of noon trading, Express Scripts ( ESRX) is down $0.40 (-0.7%) to $58.79 on light volume Thus far, 1.3 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $58.56-$59.35 after having opened the day at $58.79 as compared to the previous trading day's close of $59.19.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $48.4 billion and is part of the health services industry. The company has a P/E ratio of 33.1, above the S&P 500 P/E ratio of 17.7. Shares are up 9.6% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead